| Antibiotic Resistance in Bacteria | Lifetime | 14 | TW 1 | 99.92 |
| COVID-19 Clinical Research Studies | Lifetime | 22 | TW 1 | 99.86 |
| Streptococcal Infections and Treatments | Lifetime | 9 | TW 1 | 99.78 |
| Bacterial Identification and Susceptibility Testing | Lifetime | 8 | TW 1 | 99.85 |
| Mycobacterium research and diagnosis | Lifetime | 28 | TW 1 | 99.71 |
| SARS-CoV-2 and COVID-19 Research | Lifetime | 53 | TW 2 | 99.70 |
| Antibiotic Use and Resistance | Lifetime | 19 | TW 1 | 99.81 |
| Antibiotics Pharmacokinetics and Efficacy | Lifetime | 37 | TW 1 | 99.73 |
| Infections and bacterial resistance | Lifetime | 4 | TW 1 | 99.75 |
| Long-Term Effects of COVID-19 | Lifetime | 43 | TW 1 | 99.27 |
| Antimicrobial Resistance in Staphylococcus | Lifetime | 43 | TW 1 | 99.69 |
| Pneumonia and Respiratory Infections | Lifetime | 56 | TW 1 | 99.69 |
| Infectious Diseases and Mycology | Lifetime | 22 | TW 1 | 99.55 |
| Tuberculosis Research and Epidemiology | Lifetime | 120 | TW 1 | 99.43 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 81 | TW 1 | 99.37 |
| Vibrio bacteria research studies | Lifetime | 66 | TW 1 | 99.31 |
| Infectious Diseases and Tuberculosis | Lifetime | 95 | TW 1 | 98.97 |
| Infective Endocarditis Diagnosis and Management | Lifetime | 149 | TW 2 | 99.30 |
| Urinary Tract Infections Management | Lifetime | 93 | TW 1 | 99.16 |
| Antifungal resistance and susceptibility | Lifetime | 138 | TW 1 | 99.13 |
| Bacterial biofilms and quorum sensing | Lifetime | 126 | TW 1 | 99.12 |
| Fungal Infections and Studies | Lifetime | 123 | TW 1 | 99.05 |
| Bacterial Infections and Vaccines | Lifetime | 133 | TW 1 | 98.72 |
| Nosocomial Infections in ICU | Lifetime | 90 | TW 1 | 99.06 |
| Amoebic Infections and Treatments | Lifetime | 75 | TW 1 | 98.02 |
| SARS-CoV-2 detection and testing | Lifetime | 138 | TW 2 | 97.01 |
| Enterobacteriaceae and Cronobacter Research | Lifetime | 59 | TW 1 | 98.03 |
| COVID-19 epidemiological studies | Lifetime | 267 | TW 1 | 97.94 |
| Actinomycetales infections and treatment | Lifetime | 33 | TW 2 | 97.25 |
| COVID-19 and healthcare impacts | Lifetime | 369 | TW 1 | 95.44 |
| Diagnosis and treatment of tuberculosis | Lifetime | 178 | TW 3 | 97.68 |
| Respiratory viral infections research | Lifetime | 703 | TW 6 | 97.67 |
| Infectious Disease Case Reports and Treatments | Lifetime | 36 | TW 1 | 96.37 |
| Neutropenia and Cancer Infections | Lifetime | 367 | TW 1 | 96.91 |
| Microbial infections and disease research | Lifetime | 684 | TW 1 | 96.07 |
| Salmonella and Campylobacter epidemiology | Lifetime | 605 | TW 5 | 96.76 |
| Clostridium difficile and Clostridium perfringens research | Lifetime | 645 | TW 4 | 95.78 |
| Pharmaceutical and Antibiotic Environmental Impacts | Lifetime | 892 | TW 3 | 96.39 |
| Otolaryngology and Infectious Diseases | Lifetime | 192 | TW 1 | 92.24 |
| Neonatal and Maternal Infections | Lifetime | 573 | TW 9 | 92.64 |
| Diphtheria, Corynebacterium, and Tetanus | Lifetime | 391 | TW 1 | 87.57 |
| Burkholderia infections and melioidosis | Lifetime | 397 | TW 4 | 82.94 |
| Medical Device Sterilization and Disinfection | Lifetime | 873 | TW 3 | 68.22 |
| Antibiotic Resistance in Bacteria | 2021-2025 | 19 | TW 1 | 99.55 |
| Bacterial Identification and Susceptibility Testing | 2021-2025 | 9 | TW 1 | 99.47 |
| Antibiotics Pharmacokinetics and Efficacy | 2021-2025 | 19 | TW 1 | 99.03 |
| COVID-19 Clinical Research Studies | 2021-2025 | 328 | TW 2 | 98.43 |
| Enterobacteriaceae and Cronobacter Research | 2021-2025 | 5 | TW 1 | 96.85 |
| Antibiotic Use and Resistance | 2021-2025 | 58 | TW 1 | 98.24 |
| Streptococcal Infections and Treatments | 2021-2025 | 33 | TW 1 | 97.23 |
| Pneumonia and Respiratory Infections | 2021-2025 | 180 | TW 1 | 95.84 |
| SARS-CoV-2 and COVID-19 Research | 2021-2025 | 956 | TW 4 | 96.50 |
| Antimicrobial Resistance in Staphylococcus | 2021-2025 | 118 | TW 1 | 94.98 |
| Long-Term Effects of COVID-19 | 2021-2025 | 825 | TW 6 | 93.81 |
| Infections and bacterial resistance | 2021-2025 | 18 | TW 3 | 90.73 |
| Bacterial biofilms and quorum sensing | 2021-2025 | 293 | TW 2 | 90.64 |
| Respiratory viral infections research | 2021-2025 | 624 | TW 5 | 91.23 |
| Infectious Diseases and Mycology | 2021-2025 | 163 | TW 1 | 84.98 |
